In this issue:
PD-L1 gene amplification and nivolumab monotherapy response in NSCLC
Tepotinib in NSCLC with MET exon 14 skipping mutations
First-line durvalumab in untreated malignant pleural mesothelioma
Second-line carboplatin + etoposide vs. topotecan in sensitive relapsed SCLC
Re-examining rates in lung cancer risk after smoking cessation
Consolidation pembrolizumab after chemoradiation in unresectable stage III NSCLC
Switch maintenance chemotherapy vs. observation after carboplatin/paclitaxel in elderly advanced NSCLC
Impact of ALK rearrangements on venous and arterial thrombotic risk in NSCLC
Adjuvant chemotherapy post-SBRT for early-stage elderly NSCLC
Serum tumour markers for assessing lung cancer metastases
Please login below to download this issue (PDF)